Clinical Trial: Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07490951) titled 'Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases' on March 18.

Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.

Study Start Date: March 22

Study Type: INTERVENTIONAL

Condition: Autoimmune Diseases

Intervention: DRUG: CD19/BCMA-targeted CAR-T len...